BR112012011780A2 - peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano - Google Patents

peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano

Info

Publication number
BR112012011780A2
BR112012011780A2 BR112012011780A BR112012011780A BR112012011780A2 BR 112012011780 A2 BR112012011780 A2 BR 112012011780A2 BR 112012011780 A BR112012011780 A BR 112012011780A BR 112012011780 A BR112012011780 A BR 112012011780A BR 112012011780 A2 BR112012011780 A2 BR 112012011780A2
Authority
BR
Brazil
Prior art keywords
human
treating
melanocortin receptor
condition
human mammal
Prior art date
Application number
BR112012011780A
Other languages
English (en)
Portuguese (pt)
Inventor
Yang Wei
Shi Yi-Qun
Original Assignee
Palatin Technologies, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies, Inc filed Critical Palatin Technologies, Inc
Publication of BR112012011780A2 publication Critical patent/BR112012011780A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112012011780A 2009-11-23 2010-11-23 peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano BR112012011780A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26348609P 2009-11-23 2009-11-23
PCT/US2010/057700 WO2011063367A1 (en) 2009-11-23 2010-11-23 Melanocortin-1 receptor-specific linear peptides

Publications (1)

Publication Number Publication Date
BR112012011780A2 true BR112012011780A2 (pt) 2019-09-24

Family

ID=44060072

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011780A BR112012011780A2 (pt) 2009-11-23 2010-11-23 peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano

Country Status (13)

Country Link
US (3) US8933194B2 (https=)
EP (1) EP2504351A4 (https=)
JP (1) JP2013511554A (https=)
KR (1) KR20120102716A (https=)
CN (1) CN102712674A (https=)
AU (1) AU2010321739A1 (https=)
BR (1) BR112012011780A2 (https=)
CA (1) CA2781405A1 (https=)
EA (1) EA201290295A1 (https=)
IL (1) IL219946A0 (https=)
MX (1) MX2012005859A (https=)
WO (1) WO2011063367A1 (https=)
ZA (1) ZA201203331B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063366A1 (en) * 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
IT1404931B1 (it) * 2010-06-11 2013-12-09 Medivis S R L Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
US9441013B2 (en) 2011-05-17 2016-09-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
US9290539B2 (en) 2011-05-17 2016-03-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanotropin ligands for skin care
US9402877B2 (en) * 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
EP2814501A4 (en) 2012-03-13 2016-03-02 Tensive Controls Inc MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF
US9814755B2 (en) 2014-06-10 2017-11-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety
US9821023B2 (en) 2014-06-10 2017-11-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of central nervous system (CNS) disorders and mood disorders
US20170022252A1 (en) 2014-06-10 2017-01-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors
CN104436159A (zh) * 2014-12-09 2015-03-25 天津医科大学眼科医院 一种新型滴眼液对治疗干眼的用途
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
EP3328372A4 (en) 2015-07-28 2019-03-20 University Of Iowa Research Foundation COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
US10550157B2 (en) 2015-10-16 2020-02-04 Arizona Board Of Regent On Behalf Of The University Of Arizona Compositions and methods for treating central nervous system (CNS) disorders and mood disorders
AU2017281940C1 (en) 2016-06-24 2024-11-07 University Of Iowa Research Foundation Compositions and methods of treating melanoma
AU2017340816C1 (en) * 2016-10-04 2022-02-10 Dsm Ip Assets B.V. Melanocortin-1-receptor agonists
AU2018215619A1 (en) * 2017-02-01 2019-08-08 Clinuvel Pharmaceuticals Ltd Alpha-MSH analogues used in the treatment of xeroderma pigmentosum
EP3755346B1 (en) 2018-02-23 2024-12-04 Duke University Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
US12364715B2 (en) 2018-02-23 2025-07-22 Enzyvant Therapeutics Gmbh Methods of determining the suitability of cultured thymus tissue for implantation into humans and associated methods of use
US11819520B2 (en) * 2018-02-23 2023-11-21 Duke University Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
WO2023091689A1 (en) 2021-11-19 2023-05-25 University Of Iowa Research Foundation Combined use of mcr1-directed radiotherapy and immune checkpoint inhibition in the treatment of melanoma
US20260049105A1 (en) * 2022-08-18 2026-02-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Selective mc4r ligand for treating obesity and cognitive loss
WO2025123059A1 (en) * 2023-12-07 2025-06-12 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and uses thereof for treating substance use disorders
WO2025245244A1 (en) * 2024-05-21 2025-11-27 Endevica Bio, Inc. Non-naturally occurring melanocortin receptor agonist analogs for modulating weight loss

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731408A (en) 1985-12-20 1988-03-15 Polaroid Corporation Processable conductive polymers
US5683981A (en) 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
ATE109793T1 (de) 1987-05-22 1994-08-15 University Patents Inc Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
WO1994022460A1 (en) 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US7396814B2 (en) 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
CA2158425C (en) 1995-09-15 2003-01-28 Mac E. Hadley Diagnostic and treatment of erectile dysfunction
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
WO1998027113A2 (en) 1996-12-17 1998-06-25 Quadrant Holdings Cambridge Limited Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
US5925618A (en) * 1997-03-06 1999-07-20 American Cyanamid Company Peptides useful as somatostatin antagonists
AU7464998A (en) 1997-10-27 1999-05-17 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
GB9808229D0 (en) 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
US6284735B1 (en) 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
US6265162B1 (en) * 1998-05-05 2001-07-24 Taisei Corporation Method of identifying, detecting and monitoring microorganisms by an aromatic ring hydroxylase dioxygenase gene
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
GB9816234D0 (en) 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
CA2622786A1 (en) * 1998-10-16 2000-04-27 Naoto Oku Neovascular-specific peptides
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
DE69930873T2 (de) 1998-12-23 2007-03-15 Merck & Co., Inc. Dna-moleküle kodierende spleissvarianten des humanen melanocortin-1-rezeptorproteins
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
DK1165613T3 (da) 1999-03-29 2008-08-25 Procter & Gamble Melanocortinreceptorligander
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US7049398B1 (en) 1999-08-12 2006-05-23 Palatin Technologies, Inc. Melanocortin metallopeptide constructs, combinatorial libraries and applications
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
AU2001229491A1 (en) 2000-01-18 2001-07-31 Merck And Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
CA2405568A1 (en) * 2000-04-05 2001-10-18 North Carolina State University Prion-binding peptidic ligands and methods of using same
AU2001261363A1 (en) 2000-05-09 2001-11-20 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
GB0012370D0 (en) 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
CZ2003584A3 (cs) 2000-08-30 2003-08-13 F. Hoffmann-La Roche Ag Selektivní cyklické peptidy
RU2246501C2 (ru) 2000-09-27 2005-02-20 Дзе Проктер Энд Гэмбл Компани Лиганды меланокортиновых рецепторов
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
US7342089B2 (en) 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7345144B2 (en) 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
AU2002322466B2 (en) * 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
EP1409521A2 (en) 2001-07-12 2004-04-21 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
US7328344B2 (en) 2001-09-28 2008-02-05 Imagitas, Inc. Authority-neutral certification for multiple-authority PKI environments
FR2835528B1 (fr) 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US20030186249A1 (en) 2002-04-01 2003-10-02 Zairen Sun Human TARPP genes and polypeptides
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
JP2006511452A (ja) * 2002-07-03 2006-04-06 バイオ サイエンス インターナショナル インコーポレイテッド 芳香族ｄ−アミノ酸を含むペプチドおよびその利用方法
WO2004005324A2 (en) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US7135548B2 (en) 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
AU2003290886A1 (en) 2002-11-14 2004-06-15 Zengen, Inc. Modified alpha-msh peptides and derivatives thereof
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
BRPI0409976A (pt) 2003-05-09 2006-05-09 Novo Nordisk As composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
WO2005000338A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
CA2530024A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
US20050026948A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
ATE361294T1 (de) 2003-08-20 2007-05-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4- rezeptor-(mc4-)agonistschen peptids
EP1670815A2 (en) 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortin receptor agonists
US7989634B2 (en) 2003-11-12 2011-08-02 Lg Life Sciences Ltd. Melanocortin receptor agonists
EP1689349B9 (en) 2003-11-24 2014-02-26 Clinuvel Pharmaceuticals Limited A method of inducing melanogenesis in humans with mc1r variant alleles
US20070155660A1 (en) 2003-12-10 2007-07-05 Marsh Donald J Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
US20070123453A1 (en) 2004-03-29 2007-05-31 Heiman Mark L Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
CN1563076A (zh) 2004-04-02 2005-01-12 西南生物工程产业化中试基地有限公司 一种用于治疗性功能障碍的α－MSH类似物及制备方法
US7442693B2 (en) 2004-05-28 2008-10-28 Smithkline Beecham Corporation Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
AU2005269244B2 (en) 2004-08-04 2010-12-09 Clinuvel Pharmaceuticals Limited Methods of inducing melanogenesis in a subject.
TW200626611A (en) 2004-09-20 2006-08-01 Lonza Ag Peptide cyclisation
EP1812034A4 (en) 2004-10-08 2009-07-29 Clinuvel Pharmaceuticals Ltd COMPOSITIONS AND METHODS OF INDUCING MELANOESEES IN ONE PERSON
ME01234B (me) 2004-10-25 2013-06-20 Centocor Inc Mimetička tijela koja vezuju receptore melanokortina, smjese, postupci i upotrebe
EP1809666A2 (en) 2004-11-04 2007-07-25 Novo Nordisk A/S Peptides for use in the treating obesity
JP2008519008A (ja) 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
JP2008519009A (ja) 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
EP1809665A2 (en) 2004-11-04 2007-07-25 Novo Nordisk A/S Mc4r selective peptides and their use in the treatment of obesity
WO2006060873A1 (en) 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US7563781B2 (en) 2005-01-14 2009-07-21 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives
CN101155825B (zh) * 2005-02-09 2014-11-26 赫里克斯生物医疗公司 抗微生物六肽
US20080207493A1 (en) 2005-03-17 2008-08-28 Novo Nordisk A/S Compounds for Use in the Treatment of Obesity
CN101203527A (zh) 2005-05-31 2008-06-18 耶路撒冷希伯来大学伊森姆研究发展公司 主链环化的促黑皮质素激素（αMSH）类似物
PL2286825T3 (pl) 2005-07-08 2017-06-30 Ipsen Pharma Ligandy receptora melanokortyny
JP2009500426A (ja) 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
CN1709906A (zh) 2005-07-15 2005-12-21 中国科学技术大学 α－促黑激素的环状类似肽及其应用
AU2006271792A1 (en) 2005-07-18 2007-01-25 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP1919947B1 (en) 2005-08-26 2013-02-27 AbbVie Inc. Therapeutically active alpha-msh analogues
US20080227693A1 (en) 2005-08-29 2008-09-18 Palatin Technologies, Inc. Cyclic Peptide Isolation by Spray Drying
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
WO2008056207A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
WO2008087188A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP2106405A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2008087187A1 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
JP2010516654A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
PT2125714E (pt) 2007-03-16 2011-07-14 Pfizer Ltd Sal de cloridrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]- 5-metil-2,2-difenil-hexanamida
FR2914646A1 (fr) 2007-04-04 2008-10-10 Neorphys Soc Par Actions Simpl Analogues peptidiques des recepteurs des melanocortines
AR066175A1 (es) 2007-06-15 2009-08-05 Sod Conseils Rech Applic Ligandos del receptor de melanocortina de peptidos ciclicos
RU2010108640A (ru) 2007-09-12 2011-10-20 Глаксо Груп Лимитед (GB) Новая комбинация терапевтических агентов
NZ585131A (en) 2007-11-05 2012-10-26 Ipsen Pharma Sas Use melanocortins to treat insulin sensitivity
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
TW201002340A (en) 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011035205A2 (en) * 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
WO2011063366A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides

Also Published As

Publication number Publication date
AU2010321739A1 (en) 2012-05-31
US10106578B2 (en) 2018-10-23
KR20120102716A (ko) 2012-09-18
US20120225831A1 (en) 2012-09-06
MX2012005859A (es) 2012-12-17
US20150119341A1 (en) 2015-04-30
EP2504351A1 (en) 2012-10-03
US8933194B2 (en) 2015-01-13
WO2011063367A1 (en) 2011-05-26
US9580466B2 (en) 2017-02-28
CN102712674A (zh) 2012-10-03
EA201290295A1 (ru) 2013-01-30
EP2504351A4 (en) 2013-10-30
US20170145056A1 (en) 2017-05-25
JP2013511554A (ja) 2013-04-04
ZA201203331B (en) 2013-07-31
IL219946A0 (en) 2012-07-31
CA2781405A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
BR112012011780A2 (pt) peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
BRPI0909947A2 (pt) '' peptídeo cíclico, composição farmacêutica, método de tratamento de uma doença, indicação, condição ou síndrome mediada por receptor de melanocortina em seres humanos ou mamíferos não humanos, e, método de tratamento de condição que reage a alterações da função de receptor de melanocortina em seres humanos ou mamíferos não humanos''
BRPI0908889A2 (pt) polipeptídeo omci ou polinucleotídeo que codifica o mesmo, método para tratar ou prevenir uma doença ou condição mediada por um leucotrieno ou hidroxieicosanóide em um paciente, e, composição
BRPI1004899A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac
BRPI1008974A2 (pt) composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
BRPI1009381A2 (pt) compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
BRPI1013992A2 (pt) composições e métodos para o tratamento de resistência à insulina e diabetes melito
BRPI1013002A2 (pt) sistemas e métodos para entrega de conteúdo
BRPI1010975A2 (pt) métodos para preparar nalmefeno de naltrexona em uma reação de wittig, e para isolar o nalmefeno, e, composição farmacêutica
BR112012002137A2 (pt) método para um polipeptídeo e/ou vírus de interesse em uma cultura de célula contínua,e, composição
BRPI0815760A2 (pt) Composição dermatológica injetável para o tratamento de rugas
BR112012003077A2 (pt) mercadorias biologicas para monitorar resposta em paciente para antagonistas de vegf
BRPI0921317A2 (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BR112012008135A2 (pt) método e instrumentação para a deteção de defeitos de trilho, em particular defeitos superiores do trilho
BR112012000254A2 (pt) análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas.
FI20096188A0 (fi) Nutrigeneettisiä biomarkkereita lihavuudelle ja tyypin 2 diabetekselle
BRPI1010799A2 (pt) lactoferrina e saúde neuronal e desenvolvimento no intestino infantil
EP2401715A4 (en) CONFIGURATION AND DISTRIBUTION OF CONTENTS WHEN RECEIVED
BRPI1000030A2 (pt) métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição.
EP2546299A4 (en) RESIN COMPOSITION AND MULTILAYER STRUCTURE THEREWITH
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme
HUE050793T2 (hu) Rekombináns HCG-t tartalmazó gyógyászati készítmény
BRPI1009741A2 (pt) composição, método para prevenir ou tratar a mucosite em paciente mamífero, composição farmacêutica para adminstração tópica, e uso de uma composição
BRPI1007194A2 (pt) Composição compreendendo ácido chicórico e/ou derivados do mesmo
BRPI1007474A2 (pt) formulação para administração por via transmucosa oral de moléculas antálgicas e/ou antiespasmódicos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.